Antibacterial peptide and application thereof

A stable and low-toxicity antimicrobial peptide with a specific structure effectively addresses the limitations of existing antimicrobial peptides, effectively inhibiting a variety of fungi and bacteria, including multidrug-resistant strains.

CN119080883APending Publication Date: 2024-12-06HEFEI KS-V PEPTIDE BIOLOGICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411183188.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing antimicrobial peptides face issues of structural instability, easy inactivation, and high toxicity, limiting their effectiveness against multidrug-resistant bacteria and fungi.

Method used

Development of a broad-spectrum antimicrobial peptide with a specific structure (AB-C1-BAB-C2-L1-L2-L3-L4-C2-BAA-C1-A) using hydrophilic and hydrophobic amino acid residues, cysteine mimetics, and ring formations to enhance stability and reduce toxicity.

Benefits of technology

The proposed antimicrobial peptides exhibit high stability, low toxicity, and effective inhibitory effects on a variety of fungi and bacteria, including multidrug-resistant strains, with improved performance compared to commercial products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080883A_ABST
    Figure CN119080883A_ABST
Patent Text Reader

Abstract

The invention provides an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide has a structure as shown in a formula (I), namely A-B-C1-B-A-B-C2-L1-L2-L3-L4-C2-B-A-A-C1-A, and the structural formula is as shown in the formula (I), wherein L1, L2, L3 and L4 are independently selected from A and B respectively, and # imgabs0 # imgabs1 # n is selected from natural numbers; a is a hydrophilic amino acid residue or a mimetic thereof; b is a hydrophobic amino acid residue or a mimetic thereof; c1 is a cysteine residue or a simulant thereof, and C1 and a C1 side chain form a ring; c2 is a cysteine residue or mimetics thereof, and C2 forms a ring with the C2 side chain. The antibacterial peptide with the structure is stable in structure, not easy to inactivate, low in toxicity and relatively low in hemolytic activity, and has an inhibiting effect on various fungi and bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biotechnology, and specifically, to antimicrobial peptides and applications thereof. Background Art

[0002] The misuse of antibiotics leads to high-level drug resistance and multidrug resistance (MDR) in pathogenic microorganisms. In recent years, "superbugs" with MDR have broken out one after another around the world, seriously threatening human life and health safety. The problem of antibiotic resistance has become a major challenge to global public health. It is estimated that infections caused by antibiotic-resistant bacteria currently cause about 70,000 deaths worldwide each year. If there is no new treatment, by 2050, infections caused by multidrug-resistant bacteria may cause an additional 10 million deaths worldwide each year, exceeding cancer. Carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Enterobacteriaceae (CRE) are listed by the World Health Organization (WHO) as resistant bacteria that pose the greatest threat to human health.

[0003] In order to cope with the increasingly severe challenge of "super-resistant bacteria", in addition to modifying and improving existing antibiotics and discovering new antibiotics, researchers are also placing more hope on exploring alternatives to antibiotics to alleviate the global health security crisis caused by "super-resistant bacteria".

[0004] Antimicrobial peptides (AMPs) are a class of short peptides with a length of 10 to 50 amino acids, which are naturally produced by various organisms including fungi, plants and animals. As the first line of defense for the host against pathogen invasion, AMPs show a wide range of inhibitory activity against different Gram-positive and Gram-negative bacteria (including MDR bacteria) and fungi. Unlike traditional antibiotics that mainly work by inhibiting a certain biosynthetic pathway (such as cell wall, protein), most antimicrobial peptides inhibit or kill pathogens through multi-pathway and multi-target mechanisms such as destroying microbial membranes, increasing mitochondrial reactive oxygen levels, and destroying the cytoskeleton. Antimicrobial peptides have a unique mechanism of action, and microorganisms are not easy to develop resistance to them. Antimicrobial peptides have great potential in the clinic for the treatment of human and animal diseases, and are expected to become the best choice for solving the problems of fungal resistance and drug toxicity and side effects.

[0005] However, existing antimicrobial peptides have problems such as structural instability, easy inactivation, and high toxicity. Summary of the invention

[0006] The present application aims to solve at least one of the technical problems existing in the prior art. To this end, one purpose of the present application is to propose a broad-spectrum antimicrobial peptide with stable structure, low toxicity and the ability to inhibit a variety of fungi and bacteria.

[0007] Specifically, the technical solution of this application is as follows:

[0008] In the first aspect, the present application proposes an antimicrobial peptide. According to an embodiment of the present application, the antimicrobial peptide has a structure shown in formula (I), AB-C1-BAB-C2-L1-L2-L3-L4-C2-BAA-C1-A, formula (I);

[0009] Wherein, L1, L2, L3, and L4 are independently selected from A, B, n is selected from natural numbers, such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, etc.; A is a hydrophilic amino acid residue or its mimetic; B is a hydrophobic amino acid residue or its mimetic; C1 is a cysteine ​​residue or its mimetic, and C1 forms a ring with the side chain of C1; C2 is a cysteine ​​residue or its mimetic, and C2 forms a ring with the side chain of C2. In some examples of the present application, the antimicrobial peptides of the aforementioned structure are stable in structure, not easy to inactivate, low in toxicity, have low hemolytic activity, and have inhibitory effects on a variety of fungi and bacteria.

[0010] In the present application, fungi include Candida albicans and Aspergillus fumigatus, etc., and bacteria include Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, etc.) and Gram-negative bacteria (such as Escherichia coli, Pseudomonas aeruginosa, etc.).

[0011] It should be noted that the connection method of the above groups is from N-terminal to C-terminal. For example, the structure of L2 is used as an example, in which the N-terminal amino group of the structure is connected to the C-terminal carboxyl group of C2 to form an amide bond; the C-terminal carboxyl group is connected to the N-terminal amino group of L2 to form an amide bond. The connection method of the other groups is the same and will not be repeated here.

[0012] The above hydrophilic amino acid residues are characterized in that the side chain groups are mainly polar (e.g., charged or neutral hydrophilic). Such hydrophilic amino acid residues may be naturally occurring or non-naturally occurring. The hydrophilic amino acid residues may be mimetics of naturally occurring amino acids characterized by side chain groups that are mainly hydrophilic (charged or neutral polar). In some examples of the present application, the hydrophilic amino acid residues are selected from L-amino acid residues or D-amino acid residues.

[0013] In some specific examples of the present application, the hydrophilic amino acid residue is selected from lysine, arginine, histidine, ornithine, aspartic acid, asparagine, glutamic acid or glutamine.

[0014] The above-mentioned hydrophobic amino acid residue is characterized in that the side chain group mainly has non-polar chemical or physical properties. Such hydrophobic amino acid residues can be naturally occurring or non-naturally occurring. The hydrophobic amino acid residue can be a mimetic of a natural amino acid, characterized in that the side chain group mainly has non-polar chemical or physical properties. In some examples of the present application, the hydrophobic amino acid residue is selected from an L-amino acid residue or a D-amino acid residue.

[0015] In some specific examples of the present application, the hydrophobic amino acid residue is selected from phenylalanine, tyrosine, tryptophan, leucine, isoleucine, valine, alanine, proline, glycine, methionine, cysteine, serine or threonine.

[0016] In the above antimicrobial peptides, there is any ring structure shown in (X1)-(X5) between C1 and C1:

[0017]

[0018] in, for The antimicrobial peptide having the aforementioned structure is highly stable and not easily inactivated.

[0019] In the above antimicrobial peptides, there is any ring structure shown in (X6)-(X10) between C2 and C2:

[0020]

[0021] in, for The antimicrobial peptide having the aforementioned structure has high stability.

[0022] Based on different combinations of the above structures, the inventors constructed antimicrobial peptides with structures shown in (201)-(215):

[0023] (201)Arg-Trp-X1-Phe-Lys-Val-X6-Tyr-Lys-Gly-Ile-X6-Tyr-Lys-Lys-X1-Lys;

[0024] (202)Orn-Trp-X1-Phe-Cit-Val-X6-Tyr-Cit-Gly-Ile-X6-Tyr-Cit-Cit-X1-Cit;

[0025] (203)Arg-Trp-X1-Phe-Harg-Val-X6-Tyr-Harg-Gly-Ile-X6-Tyr-Harg-Harg-X1-Harg;

[0026] (204)Arg-2-Nal-X1-2-Nal-Lys-Val-X6-Tyr-Lys-Gly-Val-X6-2-Nal-Lys-Lys-X1-Lys;

[0027] (205)Arg-Cha-X1-Trp-Lys-Val-X6-Cha-Lys-Gly-Ile-X6-Cha-Lys-X1-Lys?

[0028] (206)Arg-Phe-X1-Trp-Lys-v-X6-Tyr-Lys-Gly-v-X6-Phe-Lys-Lys-X1-Lys;

[0029] (207)Arg-Phe-X1-Trp-Lys-Val-X8-Tyr-Lys-Gly-Ile-X8-Phe-Lys-Lys-X1-Lys?

[0030] (208)Arg-Phe-X1-Trp-Lys-Val-X6-Tyr-Lys-Gly-Ile-X6-Phe-Lys-Lys-X1-K(C12);

[0031] (209)Arg-Phe-X1-Trp-Lys-Val-X6-Tyr-Lys-Gly-Ile-X6-Phe-Lys-Lys-X1-K(C18);

[0032] (210)Arg-Phe-X1-Trp-Lys-K(C12)-X6-Tyr-Lys-Gly-Ile-X6-Phe-Lys-Lys-X1-Lys;

[0033] (211)Arg-Phe-X1-Trp-Lys-Lys-X6-Tyr-Lys-Gly-K(C12)-X6-Phe-Lys-Lys-X1-Lys;

[0034] (212)Arg-2-Nal-X1-2-Nal-Lys-Val-X8-Tyr-Lys-Gly-Val-X8-2-Nal-Lys-Lys-X1-Lys;

[0035] (213) Arg-2-Nal-X1-2-Nal-Lys-Val-X6-Tyr-Lys-Gly-Val-X6-2-Nal-Lys-Lys-X1-Lys;

[0036] (214) Arg-2-Nal-X1-2-Nal-Lys-Val-X6-Tyr-Lys-Gly-Val-X6-2-Nal-Lys-Lys-X1-Lys;

[0037] (215) Arg-2-Nal-X1-2-Nal-Lys-Val-X8-Tyr-Lys-Gly-Val-X8-2-Nal-Lys-Lys-X1-Lys;

[0038] Among them, Orn is ornithine; Cit is citrulline; Harg is homoarginine; 2-Nal is 3-(2-naphthyl)-alanine; Cha is β-cyclohexane-alanine; v is D-valine; K(C12) is lysine with 12 fatty acid chains modified on the side chain; K(C18) is lysine with 18 fatty acid chains modified on the side chain. The antimicrobial peptides of the above structures have good stability and good resistance to fungi and bacteria.

[0039] In some examples of the present application, the antimicrobial peptide has a structure shown in any one of (201) to (213) above. The antimicrobial peptides of the aforementioned structures have good stability and good resistance to fungi and bacteria.

[0040] In some preferred examples of the present application, the antimicrobial peptide has a structure shown in any one of (201) to (207) above. The antimicrobial peptides of the aforementioned structures have good stability and good resistance to fungi and bacteria.

[0041] In some preferred examples of the present application, the antimicrobial peptide has a structure shown in any one of (201), (204), and (207). The antimicrobial peptide having a structure shown in any one of (201), (204), and (207) has better stability, higher inhibitory effects on Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, and Pseudomonas aeruginosa, and is superior to commercially available antimicrobial products.

[0042] In some preferred examples of the present application, the antimicrobial peptide has a structure shown in any one of (201) and (207). The antimicrobial peptide having a structure shown in any one of (201) and (207) has better stability and antibacterial effect, and lower hemolytic activity.

[0043] In some preferred examples of the present application, the antimicrobial peptide has the structure shown in (207) above. The antimicrobial peptide having the structure shown in (207) has better stability and antibacterial effect, lower hemolysis, and has a good antibacterial effect in an ocular fungal infection model.

[0044] In a second aspect, the present application proposes a composition. According to an embodiment of the present application, the composition comprises: any of the antimicrobial peptides exemplified above. The composition comprising the antimicrobial peptides has a good inhibitory effect on fungi and bacteria.

[0045] In some examples of the present application, the composition includes but is not limited to facial cleanser, hand soap, shower gel, shampoo, mouthwash, toothpaste, soap, cosmetics, feminine care wash, laundry soap, laundry liquid, laundry powder, detergent, disinfectant or toilet cleaning liquid, etc.

[0046] In a third aspect, the present application proposes a fabric. According to an embodiment of the present application, the fabric comprises: any of the antimicrobial peptides in the above examples. The fabric having the above antimicrobial peptides has a good inhibitory effect on fungi and bacteria.

[0047] In some examples of the present application, the fabric includes but is not limited to clothing, bedding, disinfectant wipes, accessories or bandages, etc.

[0048] In a fourth aspect, the present application provides a feed. According to an embodiment of the present application, the feed comprises: any of the antimicrobial peptides in the above examples. The feed comprising the above antimicrobial peptides can delay the spoilage of the feed.

[0049] In a fifth aspect, the present application proposes a sanitary napkin. According to an embodiment of the present application, the sanitary napkin comprises: any of the antimicrobial peptides in the above examples. The sanitary napkin having the above antimicrobial peptides has a good antibacterial effect.

[0050] In a sixth aspect, the present application proposes a sanitary pad. According to an embodiment of the present application, the sanitary pad comprises: any of the antimicrobial peptides in the above examples. The sanitary pad having the above antimicrobial peptide has a good antibacterial effect.

[0051] In a seventh aspect, the present application provides a diaper. According to an embodiment of the present application, the diaper comprises: any of the antimicrobial peptides in the above examples. The diaper having the above antimicrobial peptide has a good antibacterial effect.

[0052] In an eighth aspect, the present application proposes a urine pad. According to an embodiment of the present application, the urine pad comprises: any of the antimicrobial peptides in the above examples. The urine pad having the above antimicrobial peptide has a good antibacterial effect.

[0053] In a ninth aspect, the present application proposes a pharmaceutical composition. According to an embodiment of the present application, the pharmaceutical composition comprises: any of the antimicrobial peptides exemplified above. The pharmaceutical composition comprising the antimicrobial peptides can be used to inhibit the growth of fungi or bacteria.

[0054] In the tenth aspect, the present application proposes the use of the aforementioned antimicrobial peptides in the preparation of products with antibacterial and / or bactericidal properties. These products include but are not limited to facial cleansers, hand soaps, shower gels, shampoos, mouthwashes, toothpastes, soaps, cosmetics, female care lotions, laundry soaps, laundry liquids, laundry powders, detergents, disinfectants, toilet cleaning liquids, clothing, bedding, disinfectant paper towels, accessories, bandages, sanitary napkins, sanitary pads, diapers, urine pads, food, feed, etc.

[0055] In the eleventh aspect, the present application proposes the use of the aforementioned antimicrobial peptide in the preparation of a drug for preventing and / or treating infection, wherein the infection is caused by fungi or bacteria. The aforementioned fungi include Candida albicans and Aspergillus fumigatus, etc., and the bacteria include Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, etc.) and Gram-negative bacteria (such as Escherichia coli, Pseudomonas aeruginosa, etc.).

[0056] In a twelfth aspect, the present application proposes the use of the aforementioned antimicrobial peptide in a preservative. The antimicrobial peptide of the present application can also be used as a preservative in feed or food.

[0057] In the above fabrics, sanitary napkins, sanitary pads, diapers or urine pads, the antimicrobial peptide is an active ingredient that provides antibacterial and / or bactericidal properties. Those skilled in the art have the ability to determine the appropriate content of the antimicrobial peptide.

[0058] In the above-mentioned various compositions, foods or feeds, and pharmaceutical compositions, various conventional excipients and / or active ingredients may be further contained, and the appropriate content of the antimicrobial peptides, various excipients and active ingredients of the present application can be determined according to conventional methods in the art. Those skilled in the art also know how to prepare fabrics, sanitary napkins, sanitary pads, diapers, and urine pads containing the antimicrobial peptides of the present application, including but not limited to immersing fabrics, sanitary napkins, sanitary pads, diapers, and urine pads, or materials for making fabrics, sanitary napkins, sanitary pads, diapers, and urine pads in a solution containing the antimicrobial peptides of the present application.

[0059] The antimicrobial peptides of the present application can be prepared by methods known to those skilled in the art (eg, solid phase synthesis method), and can be separated and purified by separation and purification methods known in the art (eg, high performance liquid chromatography).

[0060] It should be noted that the features and advantages described in this article for the screening method are applicable to other aspects and will not be repeated here.

[0061] Additional aspects and advantages of the present application will be given in part in the description below, and in part will become apparent from the description below, or will be learned through the practice of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0062] The above and / or additional aspects and advantages of the present application will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:

[0063] Figure 1 A schematic diagram of the chromatogram of the antimicrobial peptide 201 provided in the examples of the present application;

[0064] Figure 2 A schematic diagram of the mass spectrum of the antimicrobial peptide 201 provided in the examples of the present application;

[0065] Figure 3 A schematic diagram of the chromatogram of the antimicrobial peptide 206 provided in the examples of the present application;

[0066] Figure 4 A schematic diagram of the mass spectrum of the antimicrobial peptide 206 provided in the examples of the present application;

[0067] Figure 5 A schematic diagram of the chromatogram of the antimicrobial peptide 207 provided in the examples of the present application;

[0068] Figure 6 A schematic diagram of the mass spectrum of the antimicrobial peptide 207 provided in the examples of the present application;

[0069] Figure 7 A schematic diagram of the chromatogram of the antimicrobial peptide 208 provided in the examples of the present application;

[0070] Figure 8 A schematic diagram of the mass spectrum of the antimicrobial peptide 208 provided in the examples of the present application;

[0071] Fig. 9 A schematic diagram of the chromatogram of the antimicrobial peptide 213 provided in the examples of the present application;

[0072] Fig.10 A schematic diagram of the mass spectrum of the antimicrobial peptide 213 provided in the examples of the present application;

[0073] Fig.11 A schematic diagram of the hemolysis rate of the antimicrobial peptides 207 and 001 at different concentrations provided in the examples of the present application;

[0074] Fig.12 This is a schematic diagram of the ocular antifungal results of the antimicrobial peptide 207 provided in the examples of the present application. DETAILED DESCRIPTION

[0075] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only intended to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that those skilled in the art may make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0076] In the present application, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one of the features. In the description of the present application, "plurality" means at least two, such as two, three, etc., unless otherwise clearly and specifically defined.

[0077] In the present application, amino acids may also be represented by single-letter codes, having the following meanings: A: Ala (alanine); R: Arg (arginine); N: Asn (asparagine); D: Asp (aspartic acid); C: Cys (cysteine); Q: Gln (glutamine); E: Glu (glutamate); G: Gly (glycine); H: His (histidine); I: Ile (isoleucine); L: Leu (leucine); K: Lys (lysine); M: Met (methionine); F: Phe (phenylalanine); P: Pro (proline); S: Ser (serine); T: Thr (threonine); W: Trp (tryptophan); Y: Tyr (tyrosine); V: Val (valine).

[0078] The technology of this application is described below through specific examples. If no specific technology or conditions are specified in the examples, the technology or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0079] Example 1: Preparation of antimicrobial peptide 201

[0080] (1) Resin swelling

[0081] a) Weigh 0.2 mmol (500 mg) of Rink-Amide resin and put it into a peptide synthesis tube;

[0082] b) Add 5 ml of DMF (N,N-dimethylformamide) and 5 ml of DCM (dichloromethane) to the peptide synthesis tube and leave at room temperature for 30 minutes;

[0083] c) Use a vacuum pump to drain the solvent;

[0084] d) washing the resin with 10 ml of DMF and then draining the solvent;

[0085] Note: i) The DMF and DCM involved in this project are both common reagents with a purity of 99.7%; ii) Extracting the solvent means using a vacuum pump to extract the solvent in the peptide synthesis tube into the suction filtration bottle.

[0086] (2) Deprotection

[0087] a) Add 5 ml of 20% piperidine solution to the peptide synthesis tube to submerge the resin and blow nitrogen for 5 minutes;

[0088] b) Washing: First, rinse the resin with DMF three times (10 ml each time), and drain the solvent; then rinse the resin with DCM three times (10 ml each time), and drain the solvent; finally, rinse the resin with DMF three times (10 ml each time), and drain the solvent;

[0089] c) Add 5 ml of 20% piperidine solution into the peptide synthesis tube and blow nitrogen for 10 minutes;

[0090] d) repeating the "cleaning step b)" in the deprotection step (2);

[0091] Note: 20% piperidine solution: Use a measuring cylinder to measure 100 ml of piperidine and add DMF to the 500 ml mark on the measuring cylinder.

[0092] (3) Synthesis from the first amino acid on the right side (C-terminus) of the antimicrobial peptide 201 peptide sequence to the left side (N-terminus)

[0093] a) Weigh 0.8 mmol (238 mg) of Fmoc-Lys-OH (lysine) and 0.76 mmol (314 mg) of condensing agent (HCTU) into a 10 ml EP tube, add 6 ml of DMF to the EP tube to dissolve, shake well, and then add 1.6 mmol (264 μL) of DIEA to the EP tube;

[0094] b) Transfer the mixed solution to a peptide synthesis tube and blow nitrogen for 45 minutes;

[0095] c) Cleaning: Repeat the "cleaning step b)" in (2) deprotection.

[0096] (4) Peptide chain extension

[0097] According to the antimicrobial peptide 201 polypeptide sequence, the step (2) of deprotection and the step (3) of amino acid synthesis are continued to extend the peptide chain until the last amino acid at the N-terminus;

[0098] Note: The last amino acid used is Boc-Arg(Pbf)-OH, and the reaction steps are the same as step (3) a.

[0099] (5) Cleavage of crude peptide

[0100] Take out the peptide synthesis tube, rinse the resin with DMF three times (10 ml each time), drain the solvent after each rinse, and then rinse the resin with DCM three times (10 ml each time), drain the solvent after each rinse (drain until the resin is dry powder). After draining, prepare 30 ml of cutting reagent with a volume ratio of TFA / H2O / phenol / Tips (10 ml / 500 μL / 500 mg / 250 μL) in a 50 ml EP tube. Transfer the cutting reagent to the above-mentioned peptide synthesis tube, put it in a 26°C constant temperature shaker for oscillation reaction for 2.5 hours, take out the peptide synthesis tube, and the solution in the tube is the peptide chain cleavage solution.

[0101] (6) Crystallization

[0102] a) Transfer 30 ml of peptide chain lysate into two 50 ml EP tubes using an ear bulb, and blow dry the lysate to less than 5 ml using nitrogen at room temperature;

[0103] b) Add 40 ml of icy ether to a 50 ml EP tube, shake the tube appropriately, and then place the tube in a centrifuge at 3500 rpm for 3 min. After centrifugation, discard the supernatant.

[0104] c) repeat step b);

[0105] d) Dry at room temperature and crush after drying.

[0106] (7) Renaturation

[0107] 6 mg of the obtained crude peptide was placed in a 50 ml EP tube, 10 ml of Wahaha purified water was added to the 50 ml EP tube, and the EP tube was placed in an ultrasonic machine to ultrasonicate the crude peptide until it was completely dissolved. The pH was adjusted to 8 with ammonia water, and then 6 μL of 30% hydrogen peroxide was added, reacted for 1 hour, and sent for analysis and detection.

[0108] (8) After the refolding is completed, the refolding solution is purified by reverse phase chromatography, and the qualified fractions are collected and freeze-dried to obtain the pure antimicrobial peptide 201 with a purity of 99.5% ( Figure 1 , Figure 2 ).

[0109] Example 2: Preparation of antimicrobial peptide 202

[0110] The preparation method of antimicrobial peptide 202 is the same as that of antimicrobial peptide 201, and the difference is only in the amino acids at specific positions, including the 1st, 5th, 9th, 14th, 15th and 17th positions at the N-terminus. With reference to the preparation method of antimicrobial peptide 201, pure antimicrobial peptide 202 is obtained with a purity of 95.1%. Those skilled in the art can obtain antimicrobial peptide 202 based on the above preparation method.

[0111] Example 3: Preparation of antimicrobial peptide 203

[0112] The preparation method of antimicrobial peptide 203 is the same as that of antimicrobial peptide 201, and the difference is only in the amino acids at specific positions, including the 1st, 5th, 9th, 14th, 15th and 17th positions at the N-terminus. With reference to the preparation method of antimicrobial peptide 201, pure antimicrobial peptide 203 is obtained with a purity of 97.3%. Those skilled in the art can obtain antimicrobial peptide 203 based on the above preparation method.

[0113] Example 4: Preparation of antimicrobial peptide 204

[0114] The preparation method of antimicrobial peptide 204 is the same as that of antimicrobial peptide 201, and the difference is only in the amino acids at specific positions, including the 2nd, 4th, 11th and 13th positions at the N-terminus. With reference to the preparation method of antimicrobial peptide 201, pure antimicrobial peptide 204 is obtained with a purity of 99.6%. Those skilled in the art can obtain antimicrobial peptide 204 based on the above preparation method.

[0115] Example 5: Preparation of antimicrobial peptide 205

[0116] The preparation method of antimicrobial peptide 205 is the same as that of antimicrobial peptide 201, and the difference is only in the amino acids at specific positions, including the 2nd, 4th, 8th and 13th positions at the N-terminus. With reference to the preparation method of antimicrobial peptide 201, pure antimicrobial peptide 205 is obtained with a purity of 91.1%. Those skilled in the art can obtain antimicrobial peptide 205 based on the above preparation method.

[0117] Example 6: Preparation of antimicrobial peptide 206

[0118] (1) Resin swelling

[0119] a) Weigh 0.2 mmol (500 mg) of Rink-Amide resin and put it into a peptide synthesis tube;

[0120] b) Add 5 ml of DMF (N,N-dimethylformamide) and 5 ml of DCM (dichloromethane) to the peptide synthesis tube and leave at room temperature for 30 minutes;

[0121] c) Use a vacuum pump to drain the solvent;

[0122] d) washing the resin with 10 ml of DMF and then draining the solvent;

[0123] Note: i) The DMF and DCM involved in this project are both common reagents with a purity of 99.7%; ii) Extracting the solvent means using a vacuum pump to extract the solvent in the peptide synthesis tube into the suction filtration bottle.

[0124] (2) Deprotection

[0125] a) Add 5 ml of 20% piperidine solution to the peptide synthesis tube to submerge the resin and blow nitrogen for 5 minutes;

[0126] b) Washing: First, rinse the resin with DMF three times (10 ml each time), and drain the solvent; then rinse the resin with DCM three times (10 ml each time), and drain the solvent; finally, rinse the resin with DMF three times (10 ml each time), and drain the solvent;

[0127] c) Add 5 ml of 20% piperidine solution into the peptide synthesis tube and blow nitrogen for 10 minutes;

[0128] d) repeating the "cleaning step b)" in the deprotection step (2);

[0129] Note: 20% piperidine solution: Use a measuring cylinder to measure 100 ml of piperidine and add DMF to the 500 ml mark on the measuring cylinder.

[0130] (3) Synthesis from the first amino acid on the right side (C-terminus) of the antimicrobial peptide 206 peptide sequence to the left side (N-terminus)

[0131] a) Weigh 0.8 mmol (238 mg) of Fmoc-Lys-OH (lysine) and 0.76 mmol (314 mg) of condensing agent (HCTU) into a 10 ml EP tube, add 6 ml of DMF to the EP tube to dissolve, shake well, and then add 1.6 mmol (264 μL) of DIEA to the EP tube;

[0132] b) Transfer the mixed solution to a peptide synthesis tube and blow nitrogen for 45 minutes;

[0133] c) Cleaning: Repeat the "cleaning step b)" in (2) deprotection.

[0134] (4) Peptide chain extension

[0135] According to the antimicrobial peptide 206 polypeptide sequence, the steps (2) of deprotection and (3) of amino acid synthesis were repeated to extend the peptide chain until the last amino acid at the N-terminus. The lowercase letter v represents D-valine, and Fmoc-D-Val-OH was used as the amino acid raw material for the synthesis of the peptide fragment;

[0136] Note: The last amino acid used is Boc-Arg(Pbf)-OH, and the reaction steps are the same as step (3) a.

[0137] (5) Cleavage of crude peptide

[0138] Take out the peptide synthesis tube, rinse the resin with DMF three times (10 ml each time), drain the solvent after each rinse, and then rinse the resin with DCM three times (10 ml each time), drain the solvent after each rinse (drain until the resin is dry powder). After draining, prepare 30 ml of cutting reagent with a volume ratio of TFA / H2O / phenol / Tips (10 ml / 500 μL / 500 mg / 250 μL) in a 50 ml EP tube. Transfer the cutting reagent to the above-mentioned peptide synthesis tube, put it in a 26°C constant temperature shaker for oscillation reaction for 2.5 hours, take out the peptide synthesis tube, and the solution in the tube is the peptide chain cleavage solution.

[0139] (6) Crystallization

[0140] a) Transfer 30 ml of peptide chain lysate into two 50 ml EP tubes using an ear bulb, and blow dry the lysate to less than 5 ml using nitrogen at room temperature;

[0141] b) Add 40 ml of icy ether to a 50 ml EP tube, shake the tube appropriately, and then place the tube in a centrifuge at 3500 rpm for 3 min. After centrifugation, discard the supernatant.

[0142] c) repeat step b);

[0143] d) Dry at room temperature and crush after drying.

[0144] (7) Renaturation

[0145] 6 mg of the obtained crude peptide was placed in a 50 ml EP tube, 10 ml of Wahaha purified water was added to the 50 ml EP tube, and the EP tube was placed in an ultrasonic machine to ultrasonicate the crude peptide until it was completely dissolved. The pH was adjusted to 8 with ammonia water, and then 6 μL of 30% hydrogen peroxide was added, reacted for 1 hour, and sent for analysis and detection.

[0146] (8) After the refolding was completed, the refolding solution was purified by reverse phase chromatography, and the qualified fractions were collected and freeze-dried to obtain the pure antimicrobial peptide 206 with a purity of 95.3% ( Figure 3 , Figure 4 ).

[0147] Example 7: Preparation of antimicrobial peptide 207

[0148] (1) Resin swelling

[0149] a) Weigh 0.2 mmol (500 mg) of Rink-Amide resin and put it into a peptide synthesis tube;

[0150] b) Add 5 ml of DMF (N,N-dimethylformamide) and 5 ml of DCM (dichloromethane) to the peptide synthesis tube and leave at room temperature for 30 minutes;

[0151] c) Use a vacuum pump to drain the solvent;

[0152] d) washing the resin with 10 ml of DMF and then draining the solvent;

[0153] Note: i) The DMF and DCM involved in this project are both common reagents with a purity of 99.7%; ii) Extracting the solvent means using a vacuum pump to extract the solvent in the peptide synthesis tube into the suction filtration bottle.

[0154] (2) Deprotection

[0155] a) Add 5 ml of 20% piperidine solution to the peptide synthesis tube to submerge the resin and blow nitrogen for 5 minutes;

[0156] b) Washing: First, rinse the resin with DMF three times (10 ml each time), and drain the solvent; then rinse the resin with DCM three times (10 ml each time), and drain the solvent; finally, rinse the resin with DMF three times (10 ml each time), and drain the solvent;

[0157] c) Add 5 ml of 20% piperidine solution into the peptide synthesis tube and blow nitrogen for 10 minutes;

[0158] d) repeating the "cleaning step b)" in the deprotection step (2);

[0159] Note: 20% piperidine solution: Use a measuring cylinder to measure 100 ml of piperidine and add DMF to the 500 ml mark on the measuring cylinder.

[0160] (3) Synthesis from the first amino acid on the right side (C-terminus) of the antimicrobial peptide 207 peptide sequence to the left side (N-terminus)

[0161] a) Weigh 0.8 mmol (238 mg) of Fmoc-Lys-OH (lysine) and 0.76 mmol (314 mg) of condensing agent (HCTU) into a 10 ml EP tube, add 6 ml of DMF to the EP tube to dissolve, shake well, and then add 1.6 mmol (264 μL) of DIEA to the EP tube;

[0162] b) Transfer the mixed solution to a peptide synthesis tube and blow nitrogen for 45 minutes;

[0163] c) Cleaning: Repeat the "cleaning step b)" in (2) deprotection.

[0164] (4) Peptide chain extension

[0165] According to the antimicrobial peptide 207 polypeptide sequence, step (2) deprotection and step (3) amino acid synthesis were repeated to extend the peptide chain until DAAD was obtained.

[0166] (5) Coupling of DAAD units

[0167] a) Weigh 227 mg of 0.4 mmol DAAD-1 and HATU (140 mg, 2 eq) into a 10 ml EP tube, add 6 ml of DMF to dissolve, shake well, and then add 0.8 mmol (133 μL) of DIEA to the EP tube;

[0168] b) The mixed solution was transferred to a peptide synthesis tube and purged with nitrogen for 120 min.

[0169] (6) Peptide chain extension

[0170] According to the antimicrobial peptide 207 polypeptide sequence, step (2) deprotection and step (4) amino acid synthesis were repeated to extend the peptide chain until the second DAAD.

[0171] (7) Remove Alloc and Ally

[0172] Weigh tetrakistriphenylphosphine palladium (113 mg) and put it into a 10 ml EP tube, add 2.5 ml DMF and 2.5 ml DCM, mix well, add 124 μL phenylsilane, react for 2 h, repeat the "cleaning step b)" in (2) deprotection, and repeat the de-Alloc and de-Ally steps.

[0173] (8) Cyclization

[0174] a) Weigh Pybop (288 mg) and HOBT (105 mg) and dissolve them in 5 ml DMF. Shake well and add 1.6 mmol (264 μL) of DIEA into the EP tube.

[0175] b) Transfer the mixed solution to a peptide synthesis tube and blow nitrogen for 45 minutes;

[0176] c) Cleaning: Repeat the "cleaning step b)" in (2) deprotection.

[0177] (9) Peptide chain extension

[0178] According to the antimicrobial peptide 207 polypeptide sequence, continue to repeat step (2) deprotection and step (4) amino acid synthesis to extend the peptide chain until the last amino acid;

[0179] Note: The last amino acid used is Boc-Arg(Pbf)-OH, and the reaction steps are the same as step (3) a.

[0180] (10) Cleavage of crude peptide

[0181] Take out the peptide synthesis tube, rinse the resin with DMF three times (10 ml each time), drain the solvent after each rinse, and then rinse the resin with DCM three times (10 ml each time), drain the solvent after each rinse (drain until the resin is dry powder). After draining, prepare 30 ml of cutting reagent with a volume ratio of TFA / H2O / phenol / Tips (10 ml / 500 μL / 500 mg / 250 μL) in a 50 ml EP tube. Transfer the cutting reagent to the above-mentioned peptide synthesis tube, put it in a 26°C constant temperature shaker for oscillation reaction for 2.5 hours, take out the peptide synthesis tube, and the solution in the tube is the peptide chain cleavage solution.

[0182] (11) Crystallization

[0183] a) Transfer 30 ml of peptide chain lysate into two 50 ml EP tubes using an ear bulb, and blow dry the lysate to less than 5 ml using nitrogen at room temperature;

[0184] b) Add 40 ml of icy ether to a 50 ml EP tube, shake the tube appropriately, and then place the tube in a centrifuge at 3500 rpm for 3 min. After centrifugation, discard the supernatant.

[0185] c) repeat step b);

[0186] d) Dry at room temperature and crush after drying.

[0187] (12) Renaturation

[0188] 6 mg of the obtained crude peptide was placed in a 50 ml EP tube, 10 ml of Wahaha purified water was added to the 50 ml EP tube, and the EP tube was placed in an ultrasonic machine to ultrasonicate the crude peptide until it was completely dissolved. The pH was adjusted to 8 with ammonia water, and then 6 μL of 30% hydrogen peroxide was added, reacted for 1 hour, and sent for analysis and detection.

[0189] (13) After the refolding was completed, the refolding solution was purified by reverse phase chromatography, and the qualified fractions were collected and lyophilized to obtain the pure antimicrobial peptide 207 with a purity of 98.5% ( Figure 5 , Figure 6 ).

[0190] Example 8: Preparation of antimicrobial peptide 208

[0191] (1) Resin swelling

[0192] a) Weigh 0.2 mmol (500 mg) of Rink-Amide resin and put it into a peptide synthesis tube;

[0193] b) Add 5 ml of DMF (N,N-dimethylformamide) and 5 ml of DCM (dichloromethane) to the peptide synthesis tube and leave at room temperature for 30 minutes;

[0194] c) Use a vacuum pump to drain the solvent;

[0195] d) washing the resin with 10 ml of DMF and then draining the solvent;

[0196] Note: i) The DMF and DCM involved in this project are both common reagents with a purity of 99.7%; ii) Extracting the solvent means using a vacuum pump to extract the solvent in the peptide synthesis tube into the suction filtration bottle.

[0197] (2) Deprotection

[0198] a) Add 5 ml of 20% piperidine solution to the peptide synthesis tube to submerge the resin and blow nitrogen for 5 minutes;

[0199] b) Washing: First, rinse the resin with DMF three times (10 ml each time), and drain the solvent; then rinse the resin with DCM three times (10 ml each time), and drain the solvent; finally, rinse the resin with DMF three times (10 ml each time), and drain the solvent;

[0200] c) Add 5 ml of 20% piperidine solution into the peptide synthesis tube and blow nitrogen for 10 minutes;

[0201] d) repeating the "cleaning step b)" in the deprotection step (2);

[0202] Note: 20% piperidine solution: Use a measuring cylinder to measure 100 ml of piperidine and add DMF to the 500 ml mark on the measuring cylinder.

[0203] (3) Synthesis from the first amino acid on the right side (C-terminus) of the antimicrobial peptide 208 peptide sequence to the left side (N-terminus)

[0204] a) Weigh 0.8 mmol (362 mg) of Fmoc-Lys(alloc)-OH and 0.76 mmol (314 mg) of condensing agent (HCTU) into a 10 ml EP tube, add 6 ml of DMF to the EP tube to dissolve, shake well, and then add 1.6 mmol (264 μL) of DIEA to the EP tube;

[0205] b) Transfer the mixed solution to a peptide synthesis tube and blow nitrogen for 45 minutes;

[0206] c) Cleaning: Repeat the "cleaning step b)" in (2) deprotection.

[0207] (4) Peptide chain extension

[0208] According to the antimicrobial peptide 208 polypeptide sequence, the step (2) of deprotection and the step (3) of amino acid synthesis are continued to extend the peptide chain until the last amino acid at the N-terminus;

[0209] Note: The last amino acid used is Boc-Arg(Pbf)-OH, and the reaction steps are the same as step (3) a.

[0210] (5) Remove Alloc

[0211] Weigh tetrakistriphenylphosphine palladium (113 mg) and put it into a 10 ml EP tube, add 2.5 ml DMF and 2.5 ml DCM, mix well, add 124 μL phenylsilane, react for 2 h, repeat the "cleaning step b)" in (2) deprotection, and repeat the de-Alloc step.

[0212] (6) Dodecanoic acid coupling

[0213] a) Weigh dodecanoic acid (160 mg), Pybop (288 mg), and HOBT (105 mg) and dissolve them in 5 ml of DMF. Shake well and add 1.6 mmol (264 μL) of DIEA to the EP tube.

[0214] b) Transfer the mixed solution to a peptide synthesis tube and blow nitrogen for 45 minutes;

[0215] c) Cleaning: Repeat the "cleaning step b)" in (2) deprotection.

[0216] (7) Cleavage of crude peptide

[0217] Take out the peptide synthesis tube, rinse the resin with DMF three times (10 ml each time), drain the solvent after each rinse, and then rinse the resin with DCM three times (10 ml each time), drain the solvent after each rinse (drain until the resin is dry powder). After draining, prepare 30 ml of cutting reagent with a volume ratio of TFA / H2O / phenol / Tips (10 ml / 500 μL / 500 mg / 250 μL) in a 50 ml EP tube. Transfer the cutting reagent to the above-mentioned peptide synthesis tube, put it in a 26°C constant temperature shaker for oscillation reaction for 2.5 hours, take out the peptide synthesis tube, and the solution in the tube is the peptide chain cleavage solution.

[0218] (8) Crystallization

[0219] a) Transfer 30 ml of peptide chain lysate into two 50 ml EP tubes using an ear bulb, and blow dry the lysate to less than 5 ml using nitrogen at room temperature;

[0220] b) Add 40 ml of icy ether to a 50 ml EP tube, shake the tube appropriately, and then place the tube in a centrifuge at 3500 rpm for 3 min. After centrifugation, discard the supernatant.

[0221] c) repeat step b);

[0222] d) Dry at room temperature and crush after drying.

[0223] (9) Renaturation

[0224] 6 mg of the obtained crude peptide was placed in a 50 ml EP tube, 10 ml of Wahaha purified water was added to the 50 ml EP tube, and the EP tube was placed in an ultrasonic machine to ultrasonicate the crude peptide until it was completely dissolved. The pH was adjusted to 8 with ammonia water, and then 6 μL of 30% hydrogen peroxide was added, reacted for 1 hour, and sent for analysis and detection.

[0225] (10) After the refolding was completed, the refolding solution was purified by reverse phase chromatography, and the qualified fractions were collected and freeze-dried to obtain the pure antimicrobial peptide 208 with a purity of 96.2% ( Figure 7 , Figure 8 ).

[0226] Example 9: Preparation of antimicrobial peptide 209

[0227] The preparation method of antimicrobial peptide 209 is the same as that of antimicrobial peptide 208, and the difference is only in the amino acids at specific sites, including the 17th position at the N-terminus. With reference to the preparation method of antimicrobial peptide 208, pure antimicrobial peptide 209 is obtained with a purity of 92.6%. Those skilled in the art can obtain antimicrobial peptide 209 based on the above preparation method.

[0228] Example 10: Preparation of antimicrobial peptide 210

[0229] The preparation method of antimicrobial peptide 210 is the same as that of antimicrobial peptide 208, and the difference is only in the amino acids at specific sites, including the 6th and 17th positions at the N-terminus. With reference to the preparation method of antimicrobial peptide 208, pure antimicrobial peptide 210 is obtained with a purity of 99.3%. Those skilled in the art can obtain antimicrobial peptide 210 based on the above preparation method.

[0230] Example 11: Preparation of antimicrobial peptide 211

[0231] The preparation method of antimicrobial peptide 211 is the same as that of antimicrobial peptide 208, and the difference is only in the amino acids at specific sites, including the 6th, 11th and 17th positions at the N-terminus. With reference to the preparation method of antimicrobial peptide 208, pure antimicrobial peptide 211 is obtained with a purity of 96.4%. Those skilled in the art can obtain antimicrobial peptide 211 based on the above preparation method.

[0232] Example 12: Preparation of antimicrobial peptide 212

[0233] The preparation method of antimicrobial peptide 212 is the same as that of antimicrobial peptide 207, and the difference is only in the amino acids at specific positions, including the 2nd, 4th, 11th and 13th positions at the N-terminus. With reference to the preparation method of antimicrobial peptide 207, pure antimicrobial peptide 212 is obtained with a purity of 95.4%. Those skilled in the art can obtain antimicrobial peptide 212 based on the above preparation method.

[0234] Example 13: Preparation of antimicrobial peptide 213

[0235] (1) Resin swelling

[0236] a) Weigh 0.2 mmol (500 mg) of Rink-Amide resin and put it into a peptide synthesis tube;

[0237] b) Add 5 ml of DMF (N,N-dimethylformamide) and 5 ml of DCM (dichloromethane) to the peptide synthesis tube and leave at room temperature for 30 minutes;

[0238] c) Use a vacuum pump to drain the solvent;

[0239] d) washing the resin with 10 ml of DMF and then draining the solvent;

[0240] Note: i) The DMF and DCM involved in this project are both common reagents with a purity of 99.7%; ii) Extracting the solvent means using a vacuum pump to extract the solvent in the peptide synthesis tube into the suction filtration bottle.

[0241] (2) Deprotection

[0242] a) Add 5 ml of 20% piperidine solution to the peptide synthesis tube to submerge the resin and blow nitrogen for 5 minutes;

[0243] b) Washing: First, rinse the resin with DMF three times (10 ml each time), and drain the solvent; then rinse the resin with DCM three times (10 ml each time), and drain the solvent; finally, rinse the resin with DMF three times (10 ml each time), and drain the solvent;

[0244] c) Add 5 ml of 20% piperidine solution into the peptide synthesis tube and blow nitrogen for 10 minutes;

[0245] d) repeating the "cleaning step b)" in the deprotection step (2);

[0246] Note: 20% piperidine solution: Use a measuring cylinder to measure 100 ml of piperidine and add DMF to the 500 ml mark on the measuring cylinder.

[0247] (3) Synthesis from the first amino acid on the right side (C-terminus) of the antimicrobial peptide 213 peptide sequence to the left side (N-terminus)

[0248] a) Weigh 0.8 mmol (238 mg) of Fmoc-Lys-OH (lysine) and 0.76 mmol (314 mg) of condensing agent (HCTU) into a 10 ml EP tube, add 6 ml of DMF to the EP tube to dissolve, shake well, and then add 1.6 mmol (264 μL) of DIEA to the EP tube;

[0249] b) Transfer the mixed solution to a peptide synthesis tube and blow nitrogen for 45 minutes;

[0250] c) Cleaning: Repeat the "cleaning step b)" in (2) deprotection.

[0251] (4) Peptide chain extension: According to the peptide sequence of antimicrobial peptide 213, continue to repeat step (2) deprotection and step (3) amino acid synthesis to extend the peptide chain until the last amino acid at the N-terminus. Among them, X uses Fmoc-Cys(Mmt)-OH as the amino acid for sequence extension;

[0252] Note: The last amino acid used is Boc-Arg(Pbf)-OH, and the reaction steps are the same as step (3) a.

[0253] (5) Remove Mmt

[0254] Add 5 ml of 1% TFA / DCM solution to the peptide synthesis tube, blow nitrogen for 10 min, repeat the "cleaning step b)" in (2) deprotection, and repeat the Mmt removal step.

[0255] (6) Coupling of 1,4-di(bromomethyl)benzene

[0256] a) Weigh 1,4-di(bromomethyl)benzene (210 mg) and dissolve it in 5 ml DMF. Shake well and add 1.6 mmol (264 μL) of DIEA into the EP tube.

[0257] b) Transfer the mixed solution to a peptide synthesis tube and blow nitrogen for 45 minutes;

[0258] c) Cleaning: Repeat the "cleaning step b)" in (2) deprotection.

[0259] (7) Cleavage of crude peptide

[0260] Take out the peptide synthesis tube, rinse the resin with DMF three times (10 ml each time), drain the solvent after each rinse, and then rinse the resin with DCM three times (10 ml each time), drain the solvent after each rinse (drain until the resin is dry powder). After draining, prepare 30 ml of cutting reagent with a volume ratio of TFA / H2O / phenol / Tips (10 ml / 500 μL / 500 mg / 250 μL) in a 50 ml EP tube. Transfer the cutting reagent to the above-mentioned peptide synthesis tube, put it in a 26°C constant temperature shaker for oscillation reaction for 2.5 hours, take out the peptide synthesis tube, and the solution in the tube is the peptide chain cleavage solution.

[0261] (8) Crystallization

[0262] a) Transfer 30 ml of peptide chain lysate into two 50 ml EP tubes using an ear bulb, and blow dry the lysate to less than 5 ml using nitrogen at room temperature;

[0263] b) Add 40 ml of icy ether to a 50 ml EP tube, shake the tube appropriately, and then place the tube in a centrifuge at 3500 rpm for 3 min. After centrifugation, discard the supernatant.

[0264] c) repeat step b);

[0265] d) Dry at room temperature and crush after drying.

[0266] (9) Renaturation

[0267] 6 mg of the obtained crude peptide was placed in a 50 ml EP tube, 10 ml of Wahaha purified water was added to the 50 ml EP tube, and the EP tube was placed in an ultrasonic machine to ultrasonicate the crude peptide until it was completely dissolved. The pH was adjusted to 8 with ammonia water, and then 6 μL of 30% hydrogen peroxide was added, reacted for 1 hour, and sent for analysis and detection.

[0268] (10) After the refolding was completed, the refolding solution was purified by reverse phase chromatography, and the qualified fractions were collected and freeze-dried to obtain the pure antimicrobial peptide 213 with a purity of 96.1% ( Fig. 9 , Fig.10 ).

[0269] Example 14: In vitro antibacterial test

[0270] The antimicrobial peptide prepared based on the above example was subjected to an in vitro antibacterial test, and the specific steps were as follows:

[0271] 1. Test strains

[0272] The strains selected for in vitro antibacterial activity screening are shown in Table 1. A total of 4 strains were tested.

[0273] Source of strains: The following standard strains were purchased from ATCC.

[0274] Table 1 List of strains tested for in vitro antibacterial activity screening

[0275] Serial number Strain name Number of plants 1 Methicillin-sensitive Staphylococcus aureus ATCC29213 1 2 Streptococcus pneumoniae ATCC49619 1 3 Escherichia coli ATCC25922 1 4 Pseudomonas aeruginosa ATCC27853 1

[0276] 2. Culture medium and culture conditions

[0277] CAMHB, incubate at 35-37℃ for 16-20h and observe the results.

[0278] 3. Preparation of culture medium

[0279] Preparation of broth: Weigh an appropriate amount of CAMHB dry powder, add an appropriate amount of pure water, stir to dissolve, sterilize at 121℃ for 20 minutes, cool to room temperature and use immediately.

[0280] 4. Test methods

[0281] The MIC value of each test sample against the tested bacteria was determined by the microbroth dilution method recommended by the Clinical and Laboratory Standards Institute (CLSI) antimicrobial susceptibility test operating procedures [Methods for Dilution Antimicrobial Succeptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Eleventh Edition, M07-A11, 2018].

[0282] 1) Preparation of test samples

[0283] Weigh an appropriate amount of the test sample powder, dissolve the sample with sterile pure water or DMSO (dimethyl sulfoxide) according to the solubility of the sample, and make the concentration of the mother solution 1.28mg / mL. Take an appropriate amount of the mother solution and dilute it tenfold with sterile broth to 0.128mg / mL, and dispense half of the volume of the drug solution into the 96-well loading groove, and dilute the other half of the volume of the drug solution twice with sterile CAMHB and add it to the deep-well loading groove. Repeat the above steps to make the drug concentration in the loading groove 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.06mg / L, and use it now.

[0284] 2) Preparation of inoculum

[0285] Select several colonies from the agar plate cultured for 18-24 hours and directly prepare a bacterial suspension in sterile saline. Adjust the concentration of the bacterial suspension to 0.5 McFarland units. Dilute the corrected bacterial suspension with CAMHB to (4-8)×10 5 CFU / mL, ready for use.

[0286] 3) Sample addition and inoculation

[0287] 100 μL of the above-mentioned test sample solutions of different concentrations were respectively pipetted into the 1st to 12th wells of a sterile 96-well polystyrene plate, and 100 μL of the above-mentioned inoculum was added to each well. The final concentrations of the test samples in the wells were 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.06, and 0.03 mg / L, respectively, and the final inoculum concentrations were all (2-4)×10 5 CFU / mL. A growth control well was set up, containing 100 μL of inoculum and 100 μL of sterile CAMHB. The test substance and inoculum in each well were mixed and sealed.

[0288] 4) Incubation

[0289] The inoculated 96-well plate was placed in a 35-37°C incubator for 16-20 hours.

[0290] 5) MIC endpoint interpretation

[0291] After the culture was completed, the growth of bacteria in each well was observed, and the lowest drug concentration that completely inhibited the growth of bacteria in the well was taken as the minimum inhibitory concentration (MIC).

[0292] Quality Control

[0293] The quality control compound used was levofloxacin, and the quality control strains used were Escherichia coli ATCC25922, Staphylococcus aureus ATCC29213, Streptococcus pneumoniae ATCC49619, and Pseudomonas aeruginosa ATCC27853. The MIC reference values ​​and sensitive and resistant judgment standards refer to CLSI 2022 (Performance standards for Antimicrobial Susceptibility Testing: 32th Information Supplement.; M100), and the MIC value range of levofloxacin for standard quality control strains is shown in Table 2.

[0294] Table 2 MIC range of levofloxacin against standard quality control bacteria (criteria of CLSI 2022)

[0295] Strain name MIC(mg / L) Escherichia coli ATCC25922 0.008-0.06 Staphylococcus aureus ATCC29213 0.06-0.5 Streptococcus pneumoniae ATCC49619 0.5-2 Pseudomonas aeruginosa ATCC27853 0.5-4

[0296] CLSI 2022:Performance standards for Antimicrobial SusceptibilityTesting:32th Information Supplement.2022.

[0297] 5. Results Analysis

[0298] The results are shown in Table 3. The antimicrobial peptides 201-213 of the present application have inhibitory effects on Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae and Pseudomonas aeruginosa. Among them, the resistance of antimicrobial peptides 201, 204, and 207 to Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae and Pseudomonas aeruginosa is better than that of commercially available antimicrobial products.

[0299] Table 3 Antibacterial results

[0300]

[0301]

[0302] Note: 001 is selected from commercially available antimicrobial peptides, purchased from the Phase III clinical product of Jiangsu Pulai Pharmaceutical Biotechnology Co., Ltd.; 201-213 are antimicrobial peptides prepared in the above examples.

[0303] Example 15: Hemolytic activity assay

[0304] The hemolytic activity of the superior antimicrobial peptides 201, 204, 207 and commercially available antimicrobial peptides obtained above was determined. The specific steps are as follows:

[0305] 1. Preparation of red blood cell suspension (2%)

[0306] Take a sufficient amount of rabbit whole blood, add 10 times the amount of 0.9% sodium chloride solution, and mix well. Then centrifuge at 10000rpm for 10 minutes, remove the supernatant, and retain the precipitated red blood cells. Wash with 0.9% sodium chloride solution 2 to 3 times according to the above method, and centrifuge for the last time for 15 minutes until the supernatant is no longer red. Finally, make a 2% suspension of the accumulated red blood cells with 0.9% sodium chloride solution for use.

[0307] 2. Preparation of test solution

[0308] In an ultra-clean workbench, dilute the antimicrobial peptides in multiple ratios to prepare test solutions with drug concentrations of 5000, 2500, 1250, 625, 312.5, 156.25, 78.125, and 36.0625 μg / mL for later use.

[0309] 3. Hemolytic test method

[0310] Take 26 clean glass test tubes, test tubes numbered 1 to 16 are test tubes, tube 17 is a negative control tube, tube 18 is a positive control tube, and tubes 19 to 26 are test control tubes. Add 2% red blood cell suspension, 0.9% sodium chloride solution, and purified water in sequence as shown in Table 4, mix well, and immediately place in a 37°C air bath incubator for incubation. Observe hemolysis and agglutination reactions after 3 hours.

[0311] Table 4 Details of solution filling in each test tube

[0312] Test tube number 1~16 17 18 19~26 2% red blood cell suspension / mL 2.5 2.5 2.5 / 0.9% sodium chloride solution / mL 2.2 2.5 / 4.7 <![CDATA[Ultra-pure water (ddH2O) / mL]]> / / 2.5 / Test solution / mL 0.3 / / 0.3

[0313] If the solution in the test tube is clear red, with no cells remaining at the bottom of the tube or a small amount of red blood cells remaining, it indicates that hemolysis has occurred; if all the red blood cells sink and the supernatant is colorless and clear, or the supernatant is colored and clear but there is no obvious difference in naked eye observation between tubes 1 to 16 and 19 to 26, it indicates that no hemolysis has occurred.

[0314] If there is a brown-red or reddish-brown flocculent precipitate in the solution and it does not disperse after being gently inverted three times, it indicates that red blood cell aggregation may have occurred and the solution should be further observed under a microscope. If red blood cell aggregation is visible, it can be determined as red blood cell aggregation.

[0315] 4. Result judgment

[0316] When no hemolysis and agglutination occur in the negative control tube and hemolysis occurs in the positive control tube, if the solutions in the two parallel test tubes do not undergo hemolysis and agglutination within 3 hours, it is determined that the test sample does not undergo hemolysis at the corresponding drug concentration; if the solution in one of the two parallel test tubes undergoes hemolysis and / or agglutination within 3 hours, 4 duplicate test sample tubes should be set up separately to retest the drug at that concentration, and the solutions in the test sample tubes should not undergo hemolysis and / or agglutination within 3 hours, otherwise it is determined that the test sample undergoes hemolysis and / or agglutination at the corresponding concentration.

[0317] 5. Results Analysis

[0318] According to the hemolysis and coagulation test method of Part IV of the 2020 edition of the Pharmacopoeia of the People's Republic of China, the hemolysis condition at the bottom of each group of test tubes was observed and evaluated. The judgment results are shown in Table 5. Fig.11 , the hemolytic concentrations of antimicrobial peptides 201 and 207 were higher than 0.01, indicating that they were effective against pathogens and safe for host cells when treating infections.

[0319] Table 5 Hemolysis results of antimicrobial peptide series compounds

[0320] Sample name Hemolysis concentration Antimicrobial peptide 201 >300 μg / mL Antimicrobial peptide 204 90 μg / mL Antimicrobial peptide 207 >300 μg / mL Antimicrobial peptide 001 ≤120 μg / mL

[0321] Example 16: Ocular antifungal model evaluation test

[0322] This example uses antimicrobial peptide 207 as an example to conduct an ocular antifungal experiment, and the specific steps are as follows:

[0323] 1. Cultivation and preparation of Aspergillus fumigatus

[0324] The standard strain of Aspergillus fumigatus was inoculated on sand agar medium on a clean bench and cultured in a constant temperature incubator at 28°C for 3-4 days. When Aspergillus fumigatus grew well and covered the medium, conidia were scraped from the surface of the medium, spores and hyphae were separated by filtration, and fresh conidia suspension was prepared using PBS. Count the conidia using a hemocytometer and adjust the final concentration of the conidia suspension to 5×10 4 conidia / μL.

[0325] 2. Establishment of fungal keratitis model in mice

[0326] Mice were anesthetized by intraperitoneal injection of 4% chloral hydrate. The right cornea of ​​the mouse was scraped to injury using a disposable syringe needle under an ophthalmic surgical microscope. A microsyringe was used to extract 2 μL of spore suspension and inserted obliquely into the cornea for intracorneal injection. The left eye of the mouse was used as a blank control. The mice were killed by cervical dislocation at the corresponding time points according to the experimental arrangement, and the mouse eyeballs and corneal tissues were collected.

[0327] 3. Clinical scoring of animal models

[0328] The degree of corneal inflammation in mice was observed and scored under a slit lamp 1, 3, and 5 days after modeling. A 12-point scoring system was used to score the ulcer area, corneal opacity, and ulcer morphology. For details, see Table 6. The total score of the corneal inflammation score is the sum of the scores of the three observation indicators.

[0329] Table 6 Results of corneal inflammation

[0330]

[0331] 4. Results Analysis

[0332] The results are as follows Fig.12 As shown, antimicrobial peptide 207 has a relatively good inhibitory effect in the ocular fungal infection model.

[0333] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "illustrative embodiments", "examples", "specific examples", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner.

[0334] Although the embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the claims and their equivalents.

Claims

1. An antimicrobial peptide, characterized in that Having the structure shown in formula (I), AB-C1-BAB-C2-L1-L2-L3-L4-C2-BAA-C1-A, formula (I); Wherein, L1, L2, L3, L4 are independently selected from A, B, n is selected from natural numbers; A is a hydrophilic amino acid residue or a mimetic thereof; B is a hydrophobic amino acid residue or a mimetic thereof; C1 is a cysteine ​​residue or a mimetic thereof, and C1 forms a ring with the side chains of C1; C2 is a cysteine ​​residue or a mimetic thereof, and C2 forms a ring with the side chains of C2.

2. The antimicrobial peptide according to claim 1, characterized in that The hydrophilic amino acid residue and the hydrophobic amino acid residue are independently selected from L-amino acid residues or D-amino acid residues.

3. The antimicrobial peptide according to claim 2, characterized in that The hydrophilic amino acid residue is selected from lysine, arginine, histidine, ornithine, aspartic acid, asparagine, glutamic acid or glutamine; The hydrophobic amino acid residue is selected from phenylalanine, tyrosine, tryptophan, leucine, isoleucine, valine, alanine, proline, glycine, methionine, cysteine, serine or threonine.

4. The antimicrobial peptide according to claim 1, characterized in that The C1 and C1 have any ring structure shown by (X1)-(X5): in, for 5. The antimicrobial peptide according to claim 1, characterized in that The C2 and C2 have any ring structure shown by (X6)-(X10): in, for 6. The antimicrobial peptide according to claim 4 or 5, characterized in that Having any structure shown in (201)-(215): (201)Arg-Trp-X1-Phe-Lys-Val-X6-Tyr-Lys-Gly-Ile-X6-Tyr-Lys-Lys-X1-Lys; (202)Orn-Trp-X1-Phe-Cit-Val-X6-Tyr-Cit-Gly-Ile-X6-Tyr-Cit-Cit-X1-Cit; (203) Arg-Trp-X1-Phe-Harg-Val-X6-Tyr-Harg-Gly-Ile-X6-Tyr-Harg-Harg-X1-Harg; (204) Arg-2-Nal-X1-2-Nal-Lys-Val-X6-Tyr-Lys-Gly-Val-X6-2-Nal-Lys-Lys-X1-Lys; (205)Arg-Cha-X1-Trp-Lys-Val-X6-Cha-Lys-Gly-Ile-X6-Cha-Lys-Lys-X1-Lys; (206) Arg-Phe-X1-Trp-Lys-v-X6-Tyr-Lys-Gly-v-X6-Phe-Lys-Lys-X1-Lys; (207) Arg-Phe-X1-Trp-Lys-Val-X8-Tyr-Lys-Gly-Ile-X8-Phe-Lys-Lys-X1-Lys; (208) Arg-Phe-X1-Trp-Lys-Val-X6-Tyr-Lys-Gly-Ile-X6-Phe-Lys-Lys-X1-K (C12); (209) Arg-Phe-X1-Trp-Lys-Val-X6-Tyr-Lys-Gly-Ile-X6-Phe-Lys-Lys-X1-K (C18); (210)Arg-Phe-X1-Trp-Lys-K(C12)-X6-Tyr-Lys-Gly-Ile-X6-Phe-Lys-Lys-X1-Lys; (211)Arg-Phe-X1-Trp-Lys-Lys-X6-Tyr-Lys-Gly-K(C12)-X6-Phe-Lys-Lys-X1-Lys; (212)Arg-2-Nal-X1-2-Nal-Lys-Val-X8-Tyr-Lys-Gly-Val-X8-2-Nal-Lys-Lys-X1-Lys; (213) Arg-2-Nal-X1-2-Nal-Lys-Val-X6-Tyr-Lys-Gly-Val-X6-2-Nal-Lys-Lys-X1-Lys; (214) Arg-2-Nal-X1-2-Nal-Lys-Val-X6-Tyr-Lys-Gly-Val-X6-2-Nal-Lys-Lys-X1-Lys; (215) Arg-2-Nal-X1-2-Nal-Lys-Val-X8-Tyr-Lys-Gly-Val-X8-2-Nal-Lys-Lys-X1-Lys; Among them, Orn is ornithine; Cit is citrulline; Harg is homoarginine; 2-Nal is 3-(2-naphthyl)-alanine; Cha is β-cyclohexane-alanine; v is D-valine; K(C12) is lysine with 12 fatty acid chains modified on the side chain; K(C18) is lysine with 18 fatty acid chains modified on the side chain.

7. The antimicrobial peptide according to claim 6, characterized in that It has any structure shown in (201)-(213).

8. The antimicrobial peptide according to claim 7, characterized in that It has any structure shown in (201)-(207).

9. The antimicrobial peptide according to claim 8, characterized in that It has any structure shown in (201), (204), and (207).

10. The antimicrobial peptide according to claim 9, characterized in that It has the structure shown in any one of (201) and (207).

11. The antimicrobial peptide according to claim 10, characterized in that It has the structure shown in (207).

12. A composition, characterized in that include: The antimicrobial peptide according to any one of claims 1 to 11.

13. The composition according to claim 12, characterized in that The composition is selected from facial cleanser, hand soap, bath soap, shampoo, mouthwash, toothpaste, soap, cosmetics, female care lotion, laundry soap, laundry liquid, laundry powder, detergent, disinfectant or toilet cleaning liquid.

14. A fabric, characterized in that: include: The antimicrobial peptide according to any one of claims 1 to 11.

15. The fabric according to claim 14, characterized in that The fabric is selected from clothing, bedding, disinfectant tissue, accessories or bandages.

16. A feed, characterized in that: include: The antimicrobial peptide according to any one of claims 1 to 11.

17. A sanitary napkin, characterized in that: include: The antimicrobial peptide according to any one of claims 1 to 11.

18. A sanitary pad, characterized in that: include: The antimicrobial peptide according to any one of claims 1 to 11.

19. A diaper, characterized in that: include: The antimicrobial peptide according to any one of claims 1 to 11.

20. A urine pad, characterized in that: include: The antimicrobial peptide according to any one of claims 1 to 11.

21. A pharmaceutical composition, characterized in that include: The antimicrobial peptide according to any one of claims 1 to 11.

22. Use of the antimicrobial peptide according to any one of claims 1 to 11 in the preparation of a product having antibacterial and / or bactericidal properties.

23. Use of the antimicrobial peptide according to any one of claims 1 to 11 in the preparation of a medicament for preventing and / or treating infection, wherein: The infection is caused by fungi or bacteria.

24. Use of the antimicrobial peptide according to any one of claims 1 to 11 in preservatives.